Alumis ALMS 深 沪
等待开盘 08-18 09:30:00 美东时间
25.47
+0.160
+0.63%
华盛通- 最 高25.71
- 今 开25.05
- 成交量 16.54万股
- 最 低 24.95
- 昨 收 25.31
- 总市值 324.72万
- 52周最高 31.35
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 3.76
- 委 比 71.12%
- 总股本 0.00亿
- 历史最高 31.35
- 量 比 0.42
- 振 幅 3.00%
- 历史最低 2.7601
- 每 手 1
- 风险率 9.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per share from the same period last year. The company reported quarterly sales of $1.662 million which m...
08-14 04:59
Alumis reports strong Phase 3 data for envudeucitinib
Alumis Inc. ( ($ALMS) ) has issued an announcement. On August 10, 2026, Alumis ...
08-11 06:15
Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment
– Favorable long-term safety and tolerability profile remained consistent with previously reported data – – On track to submit a New Drug Application to FDA in 4Q 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company d...
08-11 04:24
High-flyer healthcare stocks: Ten names with strong momentum, weak valuations
Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price velocity against fu...
08-10 20:49
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
Alumis Inc. announced positive topline results from the ONWARD3 long-term extension study of envudeucitinib, showing 54% of patients achieved PASI 100 (complete skin clearance) after 48 weeks of continuous treatment. The study also demonstrated favorable safety and tolerability, consistent with previous data. Alumis plans to submit a New Drug Application to the FDA for moderate-to-severe plaque psoriasis in Q4 2026. Envudeucitinib is a next-gener...
08-10 20:05
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.
08-03 18:02
Alumis Shareholders Reelect Directors and Ratify Auditor
Alumis Inc. ( ($ALMS) ) has provided an update. On June 30, 2026, Alumis Inc. h...
07-03 05:10
MapLight Therapeutics Announces Changes to Board of Directors
MapLight Therapeutics announced the appointment of Martin Babler and Troy Cox to its Board of Directors, succeeding Robert Malenka and Jim Trenkle. Babler joins the Audit Committee, while Cox becomes Chair of the Nominating and Corporate Governance Committee. Both bring extensive experience in biotechnology leadership. Babler previously led Alumis Inc., Principia Biopharma Inc., and Talima Therapeutics, Inc., while Cox served as CEO of Foundation...
06-24 11:00
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
